These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 30346481)

  • 1. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial.
    Gross-Goupil M; Kwon TG; Eto M; Ye D; Miyake H; Seo SI; Byun SS; Lee JL; Master V; Jin J; DeBenedetto R; Linke R; Casey M; Rosbrook B; Lechuga M; Valota O; Grande E; Quinn DI
    Ann Oncol; 2018 Dec; 29(12):2371-2378. PubMed ID: 30346481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups.
    Quinn DI; Ng CF; Grande E; Kwon TG; Linke R; Lee JL; Rosbrook B; Thakur MN; Eto M; Gross-Goupil M
    ESMO Open; 2021 Jun; 6(3):100105. PubMed ID: 33901868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
    Motzer RJ; Escudier B; Tomczak P; Hutson TE; Michaelson MD; Negrier S; Oudard S; Gore ME; Tarazi J; Hariharan S; Chen C; Rosbrook B; Kim S; Rini BI
    Lancet Oncol; 2013 May; 14(6):552-62. PubMed ID: 23598172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial.
    Chamie K; Donin NM; Klöpfer P; Bevan P; Fall B; Wilhelm O; Störkel S; Said J; Gambla M; Hawkins RE; Jankilevich G; Kapoor A; Kopyltsov E; Staehler M; Taari K; Wainstein AJA; Pantuck AJ; Belldegrun AS
    JAMA Oncol; 2017 Jul; 3(7):913-920. PubMed ID: 27787547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.
    Motzer RJ; Haas NB; Donskov F; Gross-Goupil M; Varlamov S; Kopyltsov E; Lee JL; Melichar B; Rini BI; Choueiri TK; Zemanova M; Wood LA; Reaume MN; Stenzl A; Chowdhury S; Lim HY; McDermott R; Michael A; Bao W; Carrasco-Alfonso MJ; Aimone P; Voi M; Doehn C; Russo P; Sternberg CN;
    J Clin Oncol; 2017 Dec; 35(35):3916-3923. PubMed ID: 28902533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial.
    Rini BI; Melichar B; Ueda T; Grünwald V; Fishman MN; Arranz JA; Bair AH; Pithavala YK; Andrews GI; Pavlov D; Kim S; Jonasch E
    Lancet Oncol; 2013 Nov; 14(12):1233-42. PubMed ID: 24140184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis.
    Sun M; Marconi L; Eisen T; Escudier B; Giles RH; Haas NB; Harshman LC; Quinn DI; Larkin J; Pal SK; Powles T; Ryan CW; Sternberg CN; Uzzo R; Choueiri TK; Bex A
    Eur Urol; 2018 Nov; 74(5):611-620. PubMed ID: 29784193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.
    Powles T; Plimack ER; Soulières D; Waddell T; Stus V; Gafanov R; Nosov D; Pouliot F; Melichar B; Vynnychenko I; Azevedo SJ; Borchiellini D; McDermott RS; Bedke J; Tamada S; Yin L; Chen M; Molife LR; Atkins MB; Rini BI
    Lancet Oncol; 2020 Dec; 21(12):1563-1573. PubMed ID: 33284113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.
    Ravaud A; Motzer RJ; Pandha HS; George DJ; Pantuck AJ; Patel A; Chang YH; Escudier B; Donskov F; Magheli A; Carteni G; Laguerre B; Tomczak P; Breza J; Gerletti P; Lechuga M; Lin X; Martini JF; Ramaswamy K; Casey M; Staehler M; Patard JJ;
    N Engl J Med; 2016 Dec; 375(23):2246-2254. PubMed ID: 27718781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.
    Motzer RJ; Ravaud A; Patard JJ; Pandha HS; George DJ; Patel A; Chang YH; Escudier B; Donskov F; Magheli A; Carteni G; Laguerre B; Tomczak P; Breza J; Gerletti P; Lechuga M; Lin X; Casey M; Serfass L; Pantuck AJ; Staehler M
    Eur Urol; 2018 Jan; 73(1):62-68. PubMed ID: 28967554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
    Rini BI; Plimack ER; Stus V; Gafanov R; Hawkins R; Nosov D; Pouliot F; Alekseev B; Soulières D; Melichar B; Vynnychenko I; Kryzhanivska A; Bondarenko I; Azevedo SJ; Borchiellini D; Szczylik C; Markus M; McDermott RS; Bedke J; Tartas S; Chang YH; Tamada S; Shou Q; Perini RF; Chen M; Atkins MB; Powles T;
    N Engl J Med; 2019 Mar; 380(12):1116-1127. PubMed ID: 30779529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study.
    Ornstein MC; Pal SK; Wood LS; Tomer JM; Hobbs BP; Jia XS; Allman KD; Martin A; Olencki T; Davis NB; Gilligan TD; Mortazavi A; Rathmell WK; Garcia JA; Rini BI
    Lancet Oncol; 2019 Oct; 20(10):1386-1394. PubMed ID: 31427205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
    Hutson TE; Lesovoy V; Al-Shukri S; Stus VP; Lipatov ON; Bair AH; Rosbrook B; Chen C; Kim S; Vogelzang NJ
    Lancet Oncol; 2013 Dec; 14(13):1287-94. PubMed ID: 24206640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial.
    Haas NB; Manola J; Dutcher JP; Flaherty KT; Uzzo RG; Atkins MB; DiPaola RS; Choueiri TK
    JAMA Oncol; 2017 Sep; 3(9):1249-1252. PubMed ID: 28278333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial.
    Negrier S; Rioux-Leclercq N; Ferlay C; Gross-Goupil M; Gravis G; Geoffrois L; Chevreau C; Boyle H; Rolland F; Blanc E; Ravaud A; Dermeche S; Flechon A; Albiges L; Pérol D; Escudier B;
    Eur J Cancer; 2020 Apr; 129():107-116. PubMed ID: 32146304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma.
    Voss MH; Bhatt RS; Vogelzang NJ; Fishman M; Alter RS; Rini BI; Beck JT; Joshi M; Hauke R; Atkins MB; Burgess E; Logan TF; Shaffer D; Parikh R; Moazzam N; Zhang X; Glasser C; Sherman ML; Plimack ER
    Cancer; 2019 Jul; 125(14):2400-2408. PubMed ID: 30951193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Disease-free Survival in Postnephrectomy High-risk Locoregional Renal Cell Carcinoma: Analysis of the S-TRAC Trial.
    Patel A; Ravaud A; Motzer RJ; Pantuck AJ; Staehler M; Escudier B; Martini JF; Lechuga M; Lin X; George DJ
    Clin Cancer Res; 2020 Sep; 26(18):4863-4868. PubMed ID: 32546645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma.
    Karam JA; Devine CE; Urbauer DL; Lozano M; Maity T; Ahrar K; Tamboli P; Tannir NM; Wood CG
    Eur Urol; 2014 Nov; 66(5):874-80. PubMed ID: 24560330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial.
    Eisen T; Frangou E; Oza B; Ritchie AWS; Smith B; Kaplan R; Davis ID; Stockler MR; Albiges L; Escudier B; Larkin J; Bex A; Joniau S; Hancock B; Hermann GG; Bellmunt J; Hodgkinson E; Stewart GD; Barber J; Brown J; McMenemin R; Nathan P; Pickering LM; Parmar MKB; Meade A
    J Clin Oncol; 2020 Dec; 38(34):4064-4075. PubMed ID: 33052759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
    Motzer RJ; Penkov K; Haanen J; Rini B; Albiges L; Campbell MT; Venugopal B; Kollmannsberger C; Negrier S; Uemura M; Lee JL; Vasiliev A; Miller WH; Gurney H; Schmidinger M; Larkin J; Atkins MB; Bedke J; Alekseev B; Wang J; Mariani M; Robbins PB; Chudnovsky A; Fowst C; Hariharan S; Huang B; di Pietro A; Choueiri TK
    N Engl J Med; 2019 Mar; 380(12):1103-1115. PubMed ID: 30779531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.